Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Johnson & Johnson sales

This article was originally published in The Tan Sheet

Executive Summary

J&J's acquisition of Merck's stake in the European nonprescription joint venture drove 17% jump in second quarter operational growth for the firm's McNeil OTC and nutritional franchise compared with the year-ago quarter, the firm announces in a July 13 analysts call. The new McNeil Europe subsidiary will handle the launch of Zocor Heart-Pro nonprescription statin in the UK (1"The Tan Sheet" April 26, 2004, p. 6). International consumer product sales grew 14.1%, or 9%, excluding the impact of currency exchange, to $1.01 bil., compared with the second quarter of 2003. U.S. consumer sales grew 6% to $987 mil., with worldwide consumer sales totaling $2 bil., up 7.5 % excluding currency exchange...
Advertisement

Related Content

J&J Buyout Of Merck Stake In Europe Was In The Works “For Some Time”
J&J Buyout Of Merck Stake In Europe Was In The Works “For Some Time”

Topics

Advertisement
UsernamePublicRestriction

Register

PS097068

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel